FirstWord

The nod expands Gazyva beyond its established uses in blood cancers and follows its October approval for active lupus nephritis.

The authorisation of Nezglyal under "exceptional circumstances" for boys with Gd-negative brain lesions follows a 2024 negative CHMP opinion.

Jury in California finds Lilly breached the implied covenant of good faith and fair dealing in the companies' autoimmune drug collaboration.

The relocation from Deerfield will bring it "closer to one of the world's leading life sciences ecosystems, strengthening access to science, talent and partnerships."

Under the €1.165-billion ($1.3 billion) deal, Novo will explore the use of Nanexa's PharmaShell technology platform to reduce the dosing frequency of injectable therapies.

As the European Association for the Study of Diabetes (EASD) meeting approaches, FirstWord checks in on whether Western pharmas are running out of Chinese assets to in-license in metabolic disease.

Data presented at the AACR Conference on Pancreatic Cancer indicate Annamycin’s antitumor activity is partially mediated by CD8+ T cells, supporting a potential immune-mediated mechanism alongside its...

SLS009 increased apoptosis more than six-fold versus daraxonrasib in a MYC-amplified, daraxonrasib-resistant patient-derived pancreatic cancer organoid model -  Combination of SLS009 and daraxonrasib ...

— Retrospective analysis of 102 patients from the pivotal FUMANBA-1 study who had achieved MRD negativity: durable in vivo persistence of FUCASO CAR-T cells (assessed by peripheral blood vector copy n...

— Poster presentation selected for the poster discussion session (Abstract No.: PA-200): in a first-in-human study in 9 heavily pretreated, high-risk patients with relapsed/refractory multiple myeloma...